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Abstract
Background: Australian guidelines recommend that all people aged 50–70 years old actively consider taking daily low-
dose aspirin (100–300mg per day) for 2.5 to 5 years to reduce their risk of colorectal cancer (CRC). Despite the change of
national CRC prevention guidelines, there has been no active implementation of the guidelines into clinical practice.
We aim to test the efficacy of a health consultation and decision aid, using a novel expected frequency tree (EFT) to
present the benefits and harms of low dose aspirin prior to a general practice consultation with patients aged 50–70 years,
on informed decision-making and uptake of aspirin.
Methods: Approximately five to seven general practices in Victoria, Australia, will be recruited to participate.
Patients 50–70 years old, attending an appointment with their general practitioner (GP) for any reason, will be
invited to participate in the trial. Two hundred fifty-eight eligible participants will be randomly allocated 1:1
to intervention or active control arms using a computer-generated allocation sequence stratified by general
practice, sex, and mode of trial delivery (face-to-face or teletrial).
There are two co-primary outcomes: informed decision-making at 1-month post randomisation, measured by the Multi-
dimensional Measure of Informed Choice (MMIC), and self-reported daily use of aspirin at 6 months. Secondary outcomes
include decisional conflict at 1-month and other behavioural changes to reduce CRC risk at both time points.
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Discussion: This trial will test the efficacy of novel methods for implementing national guidelines to support informed
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Introduction
Background and rationale {6a}
In 2017, Cancer Council Australia published new
guidelines recommending that people aged 50–70 years
actively consider taking daily low dose aspirin to prevent
colorectal cancer (CRC) [1]. This was based on a
systematic review of the evidence and pooled data from
four aspirin cardiovascular prevention trials which
demonstrated a 25% reduced relative incidence and 33%
reduced relative mortality from CRC with a median
follow-up of 18.3 years [2]. The trials demonstrated the
benefits of aspirin were seen with low dosages which
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varied from 75mg to 300 mg per day. There is some evi-
dence from sub-group analyses of the pooled data that
taking aspirin for only 2.5–5 years may be as beneficial
as consumption for more than 5 years [2]. The effects of
aspirin on incidence and mortality appear to be stronger
for the proximal colon [2], which is important as these
tumours tend to present later and are more likely to be
missed at colonoscopy [1]. People at increased risk of
CRC, either due to their family history, or those with a
history of adenomas, are likely to have a greater absolute
benefit than those at average risk of CRC [3, 4].
There are some limitations to the evidence. Firstly, the
aspirin cardiovascular preventions trials were designed
primarily to assess the effect of aspirin on cardiovascular
outcomes rather than cancer. Secondly, except for the
Women’s Health Study (WHS), most participants in
these trials were men. In the WHS the effect on reduced
CRC incidence was observed but in modelling studies,
the cardiovascular benefit dominated the reduction in
CRC incidence [5]. Also, more recently, findings from
the ASPREE trial did not show any benefit of low-dose
aspirin in people aged over 70 in terms of all-cause mor-
tality or disability-free survival [6, 7]. The ASPREE trial
is not directly comparable as it was conducted in an
older cohort, and unlike the other studies, the reported
follow-up was only after a median of 4.7 years’ and
therefore too soon to expect any effect on cancer inci-
dence or mortality.
There is also evidence that aspirin is effective in
reducing the risk for all cancers, not just CRC [8]. A
meta-analysis of individual-level patient data from seven
cardiovascular prevention trials demonstrated a 33%
relative reduction in all cancer mortality after 5 years
follow-up, an effect which persisted to 20 years; the ef-
fect was greatest for gastrointestinal cancers, with a 35%
relative reduction in mortality within 20 years [8]. The
cancer-preventive effects of aspirin are in addition to the
established benefits in reducing cardiovascular disease
(myocardial infarcts, ischaemic strokes and transient is-
chaemic attacks [9]. Aspirin also has well-recognised
side effects including upper gastrointestinal symptoms
and increased risk of haemorrhagic stroke [10–12].
However, fatal gastrointestinal bleeding rates did not dif-
fer between aspirin and placebo groups in pooled ana-
lyses [13]. Overall, the modelled benefits substantially
outweigh potential harms from aspirin [14]. For ex-
ample, it is estimated that, for a 50-year-old, taking as-
pirin for 10 years is 10 times more likely to prevent
death than cause it, and five times more likely for some-
one aged 65 years. One death would be prevented for
every 106 men aged 50 and for every 46 men aged 65
years by taking aspirin for 10 years [14]. This evidence
has not yet been considered by Cancer Council Australia
to inform guidelines about preventing other cancers.
We have developed expected frequency trees (EFTs)
for an Australian population of 10,000 men or women
aged 50–70 which present likely outcomes over ten
years of taking aspirin for at least five years [14]. EFTs
are graphical summaries that aim to simplify multiple
conditional probabilities and present the likelihood of
specific outcomes [15]. In our previous vignette study of
304 patients aged 50–70 in Victorian general practice,
these EFTs were found to be easily understood by
patients and preferred to icon arrays as a method of
communicating the benefits and potential harms of
taking aspirin, particularly because the numbers needed
to be conveyed are small and difficult to display in an
icon array. In this study, over 70% of participants said
they would take aspirin based on the risk information
presented in the EFTs [16].
In the subsequent I-MAGIC project we obtained fur-
ther feedback about the EFTs and explored approaches
to implementing the aspirin guidelines with relevant
clinical groups. GPs, gastroenterologists, geneticists and
pharmacists recognised a potential role for themselves in
recommending aspirin, but there was consensus that
general practice holds the key to widespread implemen-
tation of the guidelines [17]. This would form part of a
larger implementation and communication strategy in
the future.
The Cancer Council Australia guidelines recognise
that the decision to take aspirin is a personal one, which
accounts for a person’s disease risk but also their
personal preferences and perceptions of the relative
benefits and harms of taking daily aspirin [18]. Decision
aids are an effective strategy for integrating research
evidence with patient values, to allow shared decision-
making. A Cochrane systematic review of 105 studies has
shown that decision aids facilitate greater patient involve-
ment, improve knowledge and increase value congruent
choices [19]. Decision aids also improve the accuracy of
patients’ risk perception and are particularly useful when
decisions require weighing up of benefits and risks which
may be preference-sensitive. Taking low dose aspirin ex-
emplifies such a decision. There are no published trials of
decision aids relating to taking aspirin to prevent cancer.
Objectives {7}
This SITA trial aims to test the efficacy of a health
consultation and use of decision aid, using an EFT to
present the benefits and harms of taking low dose
aspirin, on informed decision-making and use of aspirin
in general practice.
The two equally important objectives are to determine
if the novel-EFT based decision aid, used in a health
consultation compared with general CRC prevention
information:
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1. Increases self-reported use of aspirin at 6 months
amongst general practice patients between 50 and
70 years old, and
2. Increases informed decision-making related to
taking aspirin at 1 month in general practice
patients between 50 and 70 years old
Secondary objectives are to compare the novel EFT-
based decision aid, used in a health consultation compared
with general CRC prevention information in general prac-
tice patients between 50 and 70 years old with respect to:
1) Self-reported use of aspirin at 1 month
2) Lower mean decisional conflict at 1 month
3) Self-reported changes in other behaviours to reduce
risk of CRC (e.g. dietary, quitting smoking, or
having a screening test for CRC).
Primary hypotheses
1. An EFT-based decision aid, used in a health
consultation, will increase regular use of aspirin for
patients between 50 and 70 years old at 6 months
compared with general CRC prevention
information.
2. An EFT-based decision aid, used in a consultation,
will increase informed decision making about
aspirin use for patients between 50 and 70 years old
after 1 month compared with general CRC
prevention information.
Trial design {8}
Multi-site, phase II single-blinded randomised controlled
trial with 1:1 allocation conducted in 5–7 general practices
in Victoria, Australia, with recruitment starting in October
2020 and final follow-up to occur by the end of 2021.
Methodological frameworks
We have applied the UK Medical Research Council
Framework for the Evaluation of Complex Interventions
to inform our pre-trial research, working with end-users
to optimise the intervention [20]. This is a phase II
efficacy trial which is more appropriate for novel inter-
ventions to test if an intervention, delivered in an ‘ideal
way’, could work [21].
Methods: Participants, interventions, and
outcomes
The Victorian Cancer Agency (VCA) grant for this trial
was granted in December 2019. The COVID-19 virus
was first detected in Australia in January 2020 and by 13
March there were 140 confirmed cases which prompted
the beginning of a lockdown nationally a few weeks later
[22]. The State of Victoria has been the most heavily
affected when compared to the rest of Australia and
during the second wave of COVID-19 many people
contracted it while at work [23]. As of 15 September,
Victoria, primarily metropolitan Melbourne, where this
trial was set, recorded 19,911 out of 26,738 total cases of
coronavirus in Australia [24].
COVID-19 mitigation efforts in Victoria have included
varying degrees of self-isolation, only leaving home for
daily exercise, essentials and medical care, limited travel,
border closures and an evening curfew [25]. In response
to the lockdown there has been a 30% decline in face-to-
face GP visits and an increase in telehealth consultations
[26, 27]. To limit community transmission of COVID-19,
from 13 March 2020, new temporary Medicare Benefits
Schedule telehealth items were made available to help
provide protection for patients and health care providers
[28]. As COVID-19 has changed clinic waiting rooms and
the number of people visiting their GPs face to face, we
developed a teletrial method to deliver the trial virtually.
The teletrial methods are explained below.
Study setting {9}
This study is being conducted in three to six
metropolitan and one to two rural general practices in
Victoria, Australia.
Sample size {14}
Preliminary unpublished data from the OPTIMISE trial
[29] were used to inform sample size calculations for the
two co-primary outcomes. In this general practice trial
of an electronic multi-criteria decision analysis tool, 19%
of 1780 participants aged 50–70 years were taking daily
low dose aspirin at baseline; 34% of 38 participants in
the control arm made an informed choice related to tak-
ing aspirin at 3 months. Based on these findings, for our
trial, we assumed uptake of daily low dose aspirin at 6
months in the control arm will be 19%, given that those
already taking aspirin will be excluded from this trial,
and 34% of control participants will have made an in-
formed choice at 1 month.
For 80% power and a Bonferroni adjusted 2-sided alpha
level of 2.5% to account for the two co-primary outcomes
[29], we require 258 participants (129 per arm) to detect a
minimum 20% difference, as decided on by the trial steer-
ing committee because there is no current evidence for a
minimal clinically important difference, between interven-
tion and control arms in the (a) proportion of participants
uptake of regular aspirin use at 6months (39% vs 19%),
and (b) proportion making an informed choice about as-
pirin use at 1month (54% vs 34%). Sample size has been
inflated to allow for 10% attrition after 1month and up to
15% attrition after 6months.
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Eligibility criteria {10}
Inclusion criteria for participants
Participants will be eligible if they are (i) aged between
50 and 70 years old and have an appointment with their
GP on the day of recruitment or on the following day
(ii) able to read and understand written English, and (iii)
competent to give informed consent.
Exclusion criteria for participants
Patients will be ineligible if they (i) have
contraindications to aspirin (e.g. previous peptic ulcer,
taking anticoagulants); (ii) are already using aspirin
regularly; (iii) are unavailable over the next 6 months to
complete 1-month and 6-month follow-up question-
naires; (iv) have a previous diagnosis of bowel, endomet-
rial, ovarian or stomach cancer; (v) there is family
member with a known genetic variant associated with
Lynch syndrome; or (vi) they meet any of the following
high-risk family history criteria [30, 31]:
1. Three or more first- or second-degree relatives on
the same side of the family diagnosed with CRC or
other Lynch syndrome-related cancers
(endometrial, ovarian, gastric, pancreatic, urothelial,
renal pelvic, small intestine, biliary tract, brain).
2. Two or more first- or second-degree relatives on
the same side of the family diagnosed with CRC
including any of the following high-risk features:
multiple CRC diagnoses in the one person, a CRC
diagnosed younger than 50 years old, or a family
member with a Lynch syndrome-related cancer.
Drop out or withdrawal criteria
The trial will be stopped for intervention or control
group participants if they refuse to participate or
continue with the follow-up questionnaires for any rea-
son without explanation. The participants will have the
choice to withdraw all their data if they withdraw before
their data are analysed.
Inclusion criteria for clinics
General practices will be included if they have 3 or more
full-time equivalent GPs to ensure a sufficient volume of
potential participants.
Exclusion criteria for clinics
General practices are excluded if they have dedicated
COVID-19 testing facilities with a high volume of
symptomatic patients. This is to reduce the risk of viral
exposure to research staff.
Recruitment {15}
A visual overview of the trial recruitment can be found
in Fig. 1. Due to the impact of COVID-19 on patterns of
Fig. 1 Overview of SITA trial recruitment and data collection flow
Milton et al. Trials          (2021) 22:452 Page 5 of 17
consulting in general practice, this trial has been adapted
to include teletrial recruitment and delivery of the inter-
vention and control in addition to standard face-to-face
methods. During recruitment, two research assistants
(RA1 and RA2) work together in a general practice. RA1
will be involved in the initial approach of the patients of
the trial and RA2 will deliver the interventions after par-
ticipants are randomised.
Face-to-face approach
When in a general practice, the recruiting staff will work
closely with the practice administrative staff to identify
potentially eligible participants who have an in-clinic ap-
pointment with their GP. RA1 will send a text message
in advance of the phone call before calling patients who
have an appointment on the day or the following day. If
potential participants are interested and eligible, RA1
will schedule them in with RA2 for an appointment at
least 15 min prior to their GP appointment. RA1 will
also approach patients in the general practice waiting
room and invite them to take part in the trial if they
have not already been approached by RA1 on the phone.
If the participant is eligible and interested in participat-
ing in the trial, they will be directed to RA2 in a private
consulting room to obtain written informed consent and
enrol in the study. To ensure there is minimal impact to
general practice workflow, only participants whose GPs
are running late by at least 15 min or who have arrived
early for their appointment will be approached in the
waiting room. We have successfully applied similar re-
cruitment methods for a similar target population in the
Colorectal RISk Prediction tool (CRISP) trial [32]. This
method has been used effectively to maximise accrual
and reduce recruitment bias [33].
Teletrial approach
Based on current data during the Victorian COVID-19
outbreak, approximately 30% of GP consultations will be
delivered via a telehealth model [34]. In addition to the
face-to-face waiting room method to invite patients into
this trial, we have developed a teletrial approach both to
recruit patients and deliver the trial. Recruiting staff will
work with the administrative staff to obtain patient ap-
pointment lists to identify potentially eligible partici-
pants who have an appointment with their GP on the
day or on the following day. Patients in the target age
group will receive a text message in advance of the
phone call, warning them they will be contacted to dis-
cuss a research project being conducted at their general
practice. If the patient is eligible, the researcher will
email or send to their mobile phone the Zoom Video-
conferencing (Zoom) [35] link and the trial participant
information brochure.
Depending on whether the participant has a teletrial
or face-to-face appointment with their GP, delivery of
the trial consultations will occur either via a password-
protected zoom meeting or at the general practice before
the participant’s GP appointment (see the ‘Interventions’
section)
Who will take informed consent? {26a}
General practitioner informed consent (to allow research
staff to recruit patients in their clinics)
Members of the research team will introduce the trial to
all clinic staff in either a virtual meeting using Zoom or
in-person via a PowerPoint presentation and invite dis-
cussion about the study (Fig. 1). This includes informa-
tion about the Cancer Council Australia guidelines
relating to aspirin to reduce the risk of CRC. Each GP
will be given a participant information brochure, before
obtaining written informed consent from GPs willing to
participate, on the spot or prior to first patient recruit-
ment. General practices will be recruited via a meeting
with RA1 and RA2 and the individual GPs will provide
written consent if interested.
Patient informed consent (to test the intervention)
Trained RAs will approach patients either face-to-face,
in the practice waiting room or by telephone in advance
of a booked appointment with their GP. For the full re-
cruitment strategy, please see item in the ‘Recruitment
{15}’ section.
Eligible patients will receive a participant information
brochure either in person or via a Portable Document
Format (PDF) attached to a welcome email after a phone
call. After receiving the participant information, the
patient and RA will have an open discussion where
potential participants can ask questions about the trial.
Trained RAs will obtain informed consent from
participants in the trial. For teletrial participants,
electronic consent is captured via the study’s REDCap
database.
For face-to-face recruitment, participants will sign a
paper consent or complete the electronic consent form.
See supplementary file A and B for GP and patient con-
sent documents.
Additional consent provisions for collection and use of
participant data and biological specimens {26b}
Consent obtained in this study is specific and will not be
used for future projects. Biological specimens will not be
collected as part of this study.
Interventions
Intervention description {11a}
Participants in the intervention arm will attend a health
consultation either in person or by Zoom, delivered by a
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trained researcher, during which a decision aid for
females or males (Figs. 2 and 3) about taking aspirin to
reduce risk of CRC and other chronic conditions will be
discussed. Initially, their risk of CRC and cardiovascular
disease will be assessed qualitatively based on family
history of CRC and self-reported cardiovascular disease
risk factors collected in the baseline questionnaire. To
determine participants’ cardiovascular disease risk, RA2
will ask four questions at baseline (see baseline
questionnaire, in the Supplementary file C). If the partic-
ipants answer yes to either of the questions, they will be
told that the size of the potential benefit of using aspirin
could be greater than presented in the decision aid and
they should ask their GP about aspirin in relation to
their increased cardiovascular disease risk as well as for
CRC prevention.
Using a standardised consultation script, the decision
aid will be discussed in the context of any CRC and
Fig. 2 Tri-fold male decision aid which communicates the harms and benefits of taking aspirin for CRC prevention
Milton et al. Trials          (2021) 22:452 Page 7 of 17
cardiovascular disease risks and personal values and
preferences, allowing the participant to decide if taking
aspirin is the right decision for them.
A brief video of the decision aid will be used for both
face-to-face and teletrial delivery of the intervention. A
copy of the decision aid will be provided to intervention
participants after the video is discussed and viewed.
Teletrial participants will receive an email immediately
following the consultation with a PDF two-page version
of the decision aid and a hard copy will be posted to
them.
The decision aid is a two-page tri-fold colour bro-
chure. It includes the following information presented in
plain language: a statement of the Cancer Council
Australia recommendation; potential contraindications
to using aspirin; advice about dose and duration of tak-
ing aspirin; advice to discuss whether to take aspirin
with their GP; an EFT which presents absolute risks of
Fig. 3 Tri-fold female decision aid which communicates the harms and benefits of taking aspirin for CRC prevention
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CRC, ischaemic heart disease, stroke, all cause deaths
and gastrointestinal bleeding in a population of 10,000
Australian men or women. Please see supplementary file
F for the two-page version of the decision aid which
were included in emails to teletrial participants, file G,
and file H for the video decision aids for females and
males, respectively.
Intervention participants also receive the control arm
brochure outlining other ways to prevent CRC. They
will be encouraged to discuss aspirin use with their GP
before commencing it and will receive an SMS reminder
two weeks after enrolment to discuss aspirin with their
GP if they have not done so already.
Explanation for the choice of comparators {6b}
Control arm participants will receive, general
information about CRC prevention. The same trained
researcher, RA2 will use a standardised consultation
script to discuss a brochure (Fig. 4) and video that
covers up-to-date information about CRC prevention
Fig. 4 Tri-fold brochure for the control and intervention participants in the SITA trial, which includes advice on how to reduce the risk of CRC
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and screening from Cancer Council Victoria and Bowel
Cancer Australia including maintaining a healthy weight,
a reminder to continue CRC screening, quitting smok-
ing, eating dairy products, taking calcium supplements,
drinking less alcohol, healthy diet, being physically ac-
tive, and speaking to their GP about taking aspirin [30].
The video format for the brochure was created so that
all participants regardless of the mode of delivery
(teletrial or face-to-face) receive the information in the
same format and order. A copy of the brochure will be
provided to all participants after the video is discussed
and viewed. All teletrial participants will receive an email
immediately following the consultation with a PDF two-
page version of the control brochure and a hard copy
will be posted to them. See Supplementary file D for the
control video and file E for the control email brochure.
We will audio record 10% of the trial consultations to
ensure fidelity in delivering both intervention and the
comparator consultation scripts.
Criteria for discontinuing or modifying allocated
interventions {11b}
Participants can withdraw from the trial at any time,
without providing reason. They may elect to not be
contacted again or they may withdraw all their data
from the trial, but they will not be able to withdraw data
once it has been deidentified and aggregated.
If the RA runs out of time and participants are called
into their GP appointment before they consent or before
randomisation, they will not be included in the trial. If
the RA runs out of time after a participant is
randomised, we will give the participant the decision aid
and/or control brochure and they will be included
within the intention-to-treat analyses.
Study arm allocation is random, participants cannot
choose which arm they are in. Further, participants are
not notified of their study arm allocation, they are given
either one brochure or two brochures, it is therefore
unlikely a participant will know which arm they have
been allocated.
Strategies to improve adherence to interventions {11c}
Before commencing the trial in a general practice, we
will present the Cancer Council Australia guidelines and
contraindications to aspirin with each GP as a part of
the consenting process (see {26a}). As GPs are
commonly unaware of these guidelines [17], we will use
this discussion and the decision aid to raise awareness of
the new recommendations about aspirin. To reduce the
risk of contamination in the control arm, we will
encourage each GP to continue their normal practice
and only to respond to patients’ queries about aspirin.
Participants in the intervention arm will be
encouraged to speak with their GP about aspirin for
CRC prevention before commencing it. We will assess
the potential degree of contamination between trial arms
by measuring GP discussions about aspirin in the 6
months after randomisation through the audit of GP
medical records at 6 months.
Relevant concomitant care permitted or prohibited
during the trial {11d}
N/A
Provisions for post-trial care {30}
We do not anticipate any harm to participants during
or after the trial arising directly from the decision
aid. To ensure participant concerns, following
participation in the trial are adequately managed they
participate just before their scheduled GP
appointments and are urged to speak to their GP
about any concerns they may have.
Outcomes {12}
Outcomes will be measured at 1 and 6months.
Two co-primary outcomes will be assessed for the
trial.
1) The difference between the two-study arms in the
proportion who self-report regular adherence to
daily aspirin (i.e. taken 5 or more out of 7 days in a
week) at 6 months.
2) The difference between the two-study arms in the
proportion who have made an informed decision
about taking aspirin at 1-month measured using the
Multidimensional Measure of Informed Choice
(MMIC) [36].
Secondary outcomes include the between-arm differ-
ence in:
1) Proportion who self-reported regular adherence to
daily aspirin (i.e. taken 5 or more out of 7 days in a
week) at 1 month.
2) Mean Decisional Conflict score at 1 month
measured using the Decisional Conflict Scale
(DCS) [37]
3) Proportion who prefer to take aspirin to reduce
chances of bowel cancer at 1 month
4) Proportion of participants taking aspirin to reduce
the risk of CRC compared to those taking it to
reduce the risk of cardiovascular disease and stroke
5) Proportion of self-reported changes to the each of
the following behaviours to reduce risk of CRC at 1
month and 6 months:
 Changed diet
 Talking to their GP about quitting smoking
 Quit smoking
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 Talked to GP about completing a bowel cancer
screening test
 Completed a bowel cancer screening test
(FOBT)
 Talked to GP about colonoscopy
 Talked to GP about having a colonoscopy
 Talked to their GP about taking aspirin.
Please see supplementary files C, J and K for the
baseline, 1-month and 6-month follow-up questionnaires.
Participant timeline {13}
Table 1 shows the participant timeline.
Assignment of interventions: allocation
Sequence generation {16a}
Participants will be randomly allocated 1:1 to the
intervention or control arm. The allocation sequence
will be computer-generated by the study statistician,
stratified by general practice, brochure type based on sex
(male or female) and mode of trial delivery (face-to-face
or teletrial) using permuted blocks of random sizes. To
ensure concealment the block sizes will not be disclosed
to the recruiting staff or investigators. Participants who
did not identify as either male or female, or tick ‘other’
as their option for sex in the baseline questionnaire, will
be asked, if they had a choice between two brochures
designed for male and females which brochure they
would prefer (male or female version). Based on their
brochure preference, they will be allocated to either the
male or female stratum.
Concealment mechanism {16b}
The allocation schedule will be embedded within the
online database, REDCap, which will automatically
assign the participant after they complete the baseline
survey to either intervention or control arm ensuring
allocation concealment.
Assignment of interventions: Blinding
Who will be blinded {17a}
Participants will be told that they are participating in a
trial which aims to test information brochures about
ways to reduce their risk of CRC. They will be blinded
to the study arm allocation. The RAs will not disclose
how the information presented in the brochures differs.
Outcomes assessed by self-report obviate the need for
researcher blinding. A separate RA who is not involved
in the participant recruitment will be responsible for
ensuring follow-up of 1- and 6-month questionnaire
responses will also be blinded to study arm allocation.
Due to the nature of the study, GPs will not be
blinded to the study arm allocation as the participants
in the intervention arm are advised to speak to their
GP about taking aspirin. GPs will be provided with a
copy of each decision aid and the control brochures
but will be advised to discuss aspirin or other ways to
reduce CRC risk only if their patients specifically raise
the issue.
GP electronic medical records will be audited after 6
months to validate the self-reported adherence to aspirin
by RA1, who will be blinded to the participant
allocation.
Table 1 Participant timeline
Recruitment Enrolment Allocation Post-allocation







Aspirin decision aid X
General CRC prevention brochure X
Assessments:
Subjective numeracy scale X
Decisional conflict X
Multidimensional measure of informed choice X
Self-reported daily adherence to aspirin X
Discussion about CRC prevention with GP (GP records) X
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Procedure for unblinding if needed {17b}
We do not anticipate the need to unblind the trial. The
only potential exception would be if a participant
experienced a serious health event which could
potentially be related to the use of aspirin. In such a
circumstance, the RA who allocated the participant and
delivered the intervention will be our first point of
contact. The University of Melbourne Human Research
Ethics Committee would be contacted and the
investigators including all members on the trial steering
committee would be notified.
Data collection and management
Plans for assessment and collection of outcomes {18a}
Participants will complete a baseline questionnaire
which will be administered by the RA2 prior to
randomisation and entered directly into the RedCap trial
database, in a private consultation room. One and 6-
month follow up a link to the online questionnaires for
the patient-reported outcome measures will be sent to
each participant by either text, email, over the phone by
an RA who is not involved in recruitment or by receiv-
ing a paper copy in the post depending on their stated
preference at baseline. Participants who receive the
follow-up questionnaire by text and email will receive
two automated text or email reminders to complete the
questionnaires after 3 and 6 days and will receive a
phone call reminder by a blinded RA after 9 days. Partic-
ipants who receive the follow-up questionnaires by post
will be reminded by phone to return them 10 days after
they are posted. If the participant does not have a phone
number, we will repost the questionnaire, with a re-
minder note attached, after 2 weeks if we do not receive
back the first one.
Participant demographic characteristics collected at
baseline will include date of birth, sex (male, female or
other), postcode of residence, education level (never
completed high school, completed high school only,
TAFE qualification or similar, or University degree or
higher), country of birth, number of current medications
taken daily, living arrangements (living alone or with
others) and language spoken at home.
The validated 8-item Subjective Numeracy Scale [38]
will be administered at baseline to assess participants’
comprehension and preferences for numerical informa-
tion including probabilities, proportions, and percentages.
Four items measure people’s beliefs about their skill in
performing various mathematical operations, and four
items measure their preferences regarding the presenta-
tion of numerical information. Response values increase
left to right (1–6) for all the items, except Question 7
which is reverse coded (6–1). The scale is calculated by
taking an average across the 8-item items, with higher
scores reflecting higher subjective numeracy.
Participants’ cardiovascular disease risk factors will be
self-reported by answering the following questions (yes,
no or unsure): a family history of heart attack, angina, or
stroke; a personal history of diabetes; medication for high
blood pressure; personal history of high cholesterol; and a
personal history of smoking cigarettes. Similarly, partici-
pants’ CRC familial risk will be self-reported by answering
the following (yes, no or unsure): a family history of CRC
(parent, brother, sister, children) diagnosed before 55 years
old, and more than one relative who had CRC at any age
(parents, children, brothers, sister, grandparents, aunts,
uncles, nieces, nephews and grandchildren).
Primary outcomes
1. Self-reported regular adherence to daily aspirin (i.e.
taken 5 or more out of 7 days in a week) at 6
months as a yes/no response. Participants who
respond “not taken aspirin in the last month” or
“started and then stopped” will be coded as not
having adhered to daily aspirin use [39].
2. Informed choice to take aspirin will be measured
using MMIC, which is a composite measure of
knowledge, attitudes and behaviour [36], and has
been used in several studies of cancer screening and
genetic testing [37, 38]. We will use a set of aspirin-
specific knowledge items developed for the OPTI-
MISE trial, for which a score of eight or more con-
stitutes adequate knowledge (maximum score of 11)
[29]. An informed choice is one where a participant
has adequate knowledge and their behaviour (i.e.. to
take aspirin or not) is consistent with their attitudes
towards that behaviour (e.g. positive or negative
attitudes towards using aspirin to prevent CRC). All
other choices (i.e. with inadequate knowledge and/
or a behaviour discordant with their attitude to-
wards taking aspirin) are defined as uninformed.
Attitudes towards the decision to take aspirin will
be measured as reported in Marteau et al. [40]
(minimum total score four, maximum 28, low
scores indicating a more positive attitude, high
scores a more negative attitude). We will use the
mid-point of the scale to classify positive and
negative attitudes (scores ranging from 12 to 20).
Secondary outcomes
1) The Decisional Conflict scale has 16 items, with
three sub-domains (1) participants’ uncertainty
about making a health-related decision, (2) factors
that contribute to uncertainty, and (3) participants’
perception of how well they came to their final
decision [37]. The Decisional Conflict score (range
from 0 to 100), is calculated as the average of the
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16 items scored on a Likert scale (0 = strongly
disagree, 1 = agree, 2 = neither, 3 = disagree and 4
= strongly agree) and multiplied by 25, where 0
indicates no decisional conflict and 100 indicates an
extremely high decisional conflict. The DCS has
been widely used in the evaluation of decision aids
[41]. The inverse correlation was (r 0.16, p < 0.05)
between the decisional conflict scale and knowledge
test scores showing the validity and the test’s
acceptability [42].
2) Additional behaviours to reduce risk of CRC. At 1
and 6 months participants will be asked whether
they have done any of the following things to
reduce their chances of getting bowel cancer since
they joined the study including making changes to
their diet, talking to their GP about quitting
smoking, quitting smoking, discussed with their GP
screening for CRC by faecal occult blood test
(FOBT) or colonoscopy, completed screening for
CRC by FOBT or colonoscopy or talked to their GP
about taking aspirin.
3) Self-reported regular adherence to daily aspirin (i.e.
taken 5 or more out of 7 days in a week) at 1 month
using the same measure as for the primary outcome
at 6 months.
4) GP medical records will be audited to identify the
proportion of participants who had a consultation
in which aspirin use was discussed.
Additional descriptive measures
At 1 month, participants will be asked their
preference out of four choices to reduce their risk of
bowel cancer (change my diet, take aspirin, do the
bowel cancer screening test or unsure).
Participants who answered “yes” or “started then
stopped taking aspirin” to the questions about aspirin
adherence will be asked additional information about
the dose of aspirin they were taking (100 mg/300 mg/
other); reasons for taking aspirin (reduce risk of heart
attack, reduce risk of stroke, reduce my risk of bowel
cancer), other (please specify); whether they
experienced side-effects while taking aspirin (yes/no);
and if yes, specific side-effects (participants will be
provided with a list of the most common side-effects
including nausea, easy bruising, indigestion, and
bleeding). If they mention other side-effects that are
not listed, they will be asked to describe them. At 6
months participants will also be asked the reasons
why they did not take aspirin or why they stopped
taking aspirin.
Please see Supplementary files C, J and K for the
baseline, 1-month and 6-month follow-up questionnaires.
Plans to promote participant retention and complete
follow-up {18b}
Participants will receive a text message two weeks prior
to being sent the 1-month and 6-month follow-up ques-
tionnaires. Participants will have the option to complete
the questionnaires online (via email or text weblink),
mail or administered over the phone with an RA. Reminder
e-mails and/or phone calls will occur at pre-specified dura-
tions of non-response dependent on participants’ preferred
method of follow-up.
Participants who do not complete the follow-up ques-
tionnaires will be included in the medical record audit
6-months after baseline, unless the participant actively
withdraws consent to use their data.
Data management {19}
Data will be collected on site in general practices and
recorded directly in REDCap for all participants. The
REDCap database will only be accessible by authorised
university trial staff. REDCap is password protected with
multi-factor authentication for additional security. The
REDCap database has mandatory data entry fields to re-
duce missing data. Before randomisation, there is a
check in REDCap to ensure accurate entry of the strati-
fying variables. All paper-based, will be entered directly
into REDCap by an RA who was not involved in recruit-
ing the participants, follow-up questionnaires will be
stored securely in an office within the Victorian Com-
prehensive Cancer Centre in a locked file cabinet; all
data will only be accessible to the listed researchers.
Confidentiality {27}
Research data will be stored in accordance with the
University of Melbourne’s Research Data Management
Policy and Research Code of Conduct and will be stored
on University managed and/or sanctioned storage
infrastructure. Data will be secured via a personal login
and data elements restricted by role at the direction of
the Chief Investigator. After data collection, all
identifiers such as participant names will be removed
and replaced by a code. Electronic data will be re-
identifiable for the duration of project. Participant con-
tact information (phone number and email address) will
be stored in a quarantined area on REDCap, only visible
to members of the research team who require it for
study-related contact. This restriction will be built into
REDCap user roles. Personal identifiers will be removed
at trial completion, and only non-identifiable data will
be stored subsequently. Paper-based data will be
destroyed using confidential waste management services
five years after the publication of the results.
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Statistical methods
Statistical methods for primary and secondary outcomes
{20a}
Descriptive statistics will be used to compare baseline
measures between the two study arms. These include
participant demographic characteristics, subjective
numeracy score, self-reported cardiovascular risk and
family history of bowel cancer. All randomised partici-
pants will be included in the main analysis in their
assigned study arms in accordance with the intention-
to-treat principle [43].
The two co-primary outcomes, (1) proportion of par-
ticipants who are taking regular aspirin at 6 months and
(2) proportion of participants who make an informed
choice about taking aspirin at 1 month, will each be
compared between the two study arms using logistic re-
gression with general practice, brochure type based on
sex (male or female) and mode of trial delivery (face-to-
face or teletrial) included as covariates.
We will also use logistic regression for the secondary
binary outcomes and linear regression for the
continuous outcomes, and all regression analyses will be
adjusted for the randomisation stratification factors.
The estimated intervention effect will be reported as
the odds ratio for binary outcomes and the difference in
means between the intervention and control arms for
continuous outcomes. Estimates for the co-primary out-
comes will be reported with Bonferroni adjusted 95%
confidence intervals and p values. Estimates for second-
ary outcomes will be reported with respective 95% confi-
dence intervals and p values with no adjustments for
multiplicity [44].
All analyses will be conducted using Stata 15 [45].
Interim analyses {21b}
We do not plan to conduct an interim analysis for this
trial.
Methods for additional analyses (e.g. subgroup analyses)
{20b}
A sensitivity analysis may be performed on the primary
and secondary outcomes to adjust for additional pre-
specified baseline variables in the regression models.
These include age in years, sex and family history of
colorectal cancer, cardiovascular disease risk and sub-
jective numeracy scores.
Exploratory sub-group analyses are planned by face-
to-face versus teletrial, brochure type (male/female),
cardiovascular risk, family history of bowel cancer,
number of medications, and Socio-Economic Indexes
for Areas (SEIFA) based on participants’ postcode of
residence [46].
Methods in analysis to handle protocol non-adherence
and any statistical methods to handle missing data {20c}
An adherence adjusted analysis will be conducted for
the two co-primary outcomes using a complier average
casual effect (CACE) analysis [47]. Multiple imputation
may be used to handle the missing data if appropriate. A
sensitivity analysis using pattern-mixture model will as-
sess the robustness of the missing data assumption. A
detailed analysis plan will be developed for the second-
ary and sensitivity analyses.
Plans to give access to the full protocol, participant level-
data and statistical code {31c}
Only the study team will have access to the participant-
level dataset stored in REDCap. All the authors will have
access to the full protocol.
The statistical code including allocation schedule will
only be available to the trial statistician and PhD
candidate.
Oversight and monitoring
Composition of the coordinating centre and trial steering
committee {5d}
Principal investigators and PhD Candidate
Design and conduct of SITA
Decide when site clinics visits occur
Preparation of protocol and revisions
Organising steering committee meetings
Publication of study reports
Data management
Maintenance of trial data management system
REDCap, and entry of study data
Steering committee (SC)
(see title page for members)
Agreement of final protocol
Reviewing progress of study and if necessary, agreeing
changes to the protocol to facilitate the smooth running
of the study.
Recruitment team including RAs
Study planning
Organisation of steering committee meetings
Provide annual risk report MHRA [Victorian Cancer
Agency] and ethics committee
Recruitment of patients and liaising with the principle
investigator





Delivery of intervention to intervention or control
participants
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Composition of the data monitoring committee, its role
and reporting structure {21a}
This trial is testing the efficacy of a decision aid; any
final decisions to take aspirin will be left to the
participant in discussion with their GP. The intervention
itself therefore is relatively low risk. This is a relatively
small phase II efficacy trial. We do not expect significant
adverse effects arising from the trial itself. We have
therefore decided not to have a separate data monitoring
committee. Oversight of the trial will be managed by the
trial steering committee.
Adverse event reporting and harms {22}
This study aims to allow participants to make an
informed choice about following a nationally recommended
approach to reduce CRC risk: taking low dose aspirin.
We recommend that participants who are considering
taking aspirin discuss it with their GP to ensure it is
safe for them. The potential risks of involvement
therefore relate to those of decision-making and not
of taking aspirin. These include low risk of anxiety in
discussing CRC risk and uncertainty about options to
reduce that risk. There is potential for participants to
experience side effects from taking aspirin if they
choose to take aspirin after discussion with their GP.
All participants will be monitored by their GP if they
commence taking aspirin and are advised to see their
GP if concerns about potential side effects arise. We
are collecting side-effects and adverse events from
self-report and audit of the GP medical records.
Frequency and plans for auditing trial conduct {23}
The recruitment team will meet weekly with the
principal investigator (J Emery) to discuss the progress
of the data collection and analysis and be on hand to
manage any unforeseen situations including adverse
events relating to aspirin use. The Trial Steering
Committee of investigators named on the VCA grant
will meet quarterly to discuss all aspects of the trial and
progress. Overall progress will be reported to the VCA
every 6 months. There will be no independent auditing
of trial conduct.
Plans for communicating important protocol
amendments to relevant parties (e.g. trial participants,
ethical committees) {25}
Any important protocol modifications will be discussed
with the investigators and reported to the University of
Melbourne’s Faculty of Medicine, Dentistry and Health
Science’s Human Research Ethics Sub-Committee.
Additionally, any modification in the protocol will also
be updated in the ANZCTR. It is unlikely any significant
changes necessitating participant communication will be
made to the protocol, therefore there is no specific plan
to communicate these changes. If needed, plans will be
made to communicate these changes to participants
accordingly.
Dissemination plans {31a}
The results of this trial will be published in a peer-
reviewed journal and reported at peer-reviewed scientific
conferences and meetings.
The Primary Care Collaborative Cancer Clinical Trials
Group (PC4) has a well-established communication
strategy that would include the following: media releases
to a health professional and general outlets; Twitter and
other social media outlets; PC4 Research Round-up and
other health professional and general podcasts; dissem-
ination via the PC4 Consumer Advisory Group and their
respective consumer networks. We would use all these
approaches to promote the trial results and the decision
aid. In addition, at the end of the trial we will hold a
Think Tank involving key researchers, clinicians (e.g.
GPs, gastroenterologists, practice nurses) and their
representative colleges (RACGP, ACCRM, GESA,
APNA), consumers and consumer organisations (e.g.
Cancer Council Victoria, Bowel Cancer Australia), and
health policy makers from the Victorian Department of
Health and Human Services Prevention and Population
Health Branch, Cancer Institute NSW, and Cancer
Australia. We will specifically identify and invite repre-
sentatives of rural GPs and consumers. At this event, we
would present the key findings of the research and plan
a range of strategies to promote the results and their
uptake into practice. The Think Tank would be funded
by PC4.
Discussion
Aspirin can reduce the risk of developing CRC by up to
25% and the benefits outweigh the risks of taking it for
most people aged 50–70 years [48]. Australia is the first
country to have national guidelines recommending all
people aged 50 to 70 consider low dose aspirin to
prevent CRC, irrespective of other disease risks [13].
Decision aids are interventions with the potential to
support informed choice by improving the following
factors: knowledge, clarity of personal values, and
implementation of an intention [49]. This trial is the first
to develop and determine whether a decision aid is
effective in increasing uptake and supporting an informed
choice for patients aged 50–70 years about taking aspirin
to prevent CRC and other common conditions.
We have developed a teletrial model in addition to
previous waiting room methods (37) to administer the
trial. By aiming to incorporate the teletrial methods we
hope to capture general practice patients who have an
appointment with their GP via telehealth who will not
be visiting the practice. The uptake of telehealth
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consultations with GPs was approximately 30% between
April and June 2020 in Australia as a result of COVID-19
[34]. Many non-COVID trials have been paused during
this time which resulted in the need for an innovative ap-
proach to including study participants in this trial [50].
This trial will create new evidence on the efficacy of a
decision aid about aspirin to reduce risk of CRC and
CVD on aspirin use and informed decision-making. It
will inform future models to implement Australian
guidelines about using aspirin to prevent CRC.
Trial status
The trial was approved by the University of Melbourne’s
Medicine and Dentistry Human Ethics Sub-Committee
on 28-Jul-2020.
This is version 5.0 of the protocol. The date of
submission: 01/04/2021
The planned dates for recruitment are September
2020 and completion of recruitment August 2021.
Trial registration
The Australian New Zealand Clinical Trials Registry
(ANZCTR) ACTRN12620001003965.
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